On December 3, 2019 IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, reported that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 12:30 p.m. Eastern Time (Press release, IntelGenx, DEC 3, 2019, View Source [SID1234551876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be broadcast live and archived on the Company’s website at www.intelgenx.com under "Presentations" in the Investors section.

On December 3, 2019 Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), reported the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease (Press release, Immunomedics, DEC 3, 2019, View Source [SID1234551873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We appreciate FDA’s guidance during the resubmission period and look forward to working closely with the Agency during the BLA review," said Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. "We are pleased to have reached this important milestone and believe that sacituzumab govitecan, if approved, could become an important new treatment option for patients with late-stage mTNBC."

On December 3, 2019 FORMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, reported that the company will present at two meetings in December (Press release, Forma Therapeutics, DEC 3, 2019, View Source [SID1234551872]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

31st Annual Piper Jaffray Healthcare Conference, Thursday, Dec. 5, 2019 at 8:10 a.m. EST in New York, NY.
FORMA Investor Lunch at the 2019 ASH (Free ASH Whitepaper) Annual Meeting, Monday, Dec. 9, 2019 at 12:00 p.m. EST at the Hilton Orlando. Presentations will highlight FT-4202, a novel, selective pyruvate kinase-R (PKR) activator in sickle cell disease, and olutasidenib, an IDH1m inhibitor that acts as a single agent or in combination with azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome. This event will be webcast and can be accessed through FORMA Therapeutics Investor page. A replay of the webcast will be available approximately two hours after the completion of the live event.

On December 3, 2019 DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that Mr. Saiid Zarrabian, Chief Executive Officer of DelMar, will be a featured presenter at the LD Micro Invitational Conference on December 10, 2019 at 2:40 pm PST, at the Luxe Sunset Boulevard Hotel in Los Angeles, CA (Press release, DelMar Pharmaceuticals, DEC 3, 2019, View Source [SID1234551871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will also be available for one-on-one meetings.

For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

On December 3, 2019 ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, reported that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares ("ADSs") at a public offering price of $2.50 per ADS (Press release, ASLAN Pharmaceuticals, DEC 3, 2019, View Source [SID1234551870]). Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $12.8 million. All of the ADSs in the offering are being sold by ASLAN.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, ASLAN has granted the underwriter an option, exercisable at any time through and until one day before the closing date of this offering, to purchase up to an additional 768,679 ADSs at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about 5 December 2019, subject to customary closing conditions. The aggregate offering amount, including the underwriter’s option, reflects the maximum market value of securities that ASLAN is allowed to sell under "baby shelf" rules currently applicable to its effective shelf registration statement on Form F-3.